Back to TMO Overview
NYQ · Valuation Lab
TMO
Thermo Fisher Scientific Inc
Last$577.83
Market cap213.7B
EV/EBITDA21.4x
Intrinsic value
$409.73
MoS -41.0% · Overvalued
Assuming 13.5% FCF margin and 10.5% Y1–5 growth.
Upside to price
EV (DCF)190B
Terminal share65%
Expected IV$442.94
Probability weights
Projected free cash flows
Stage FCF path with present values · terminal 65% of EV
PV of stage FCFs66.8B
PV of terminal value123.1B
Enterprise value190B
Net cash / (debt)-38.5B
Equity value151.5B
Intrinsic value / share$409.73
| Year | Revenue | FCF | PV | DF |
|---|---|---|---|---|
| Y1 | 51.2B | 6.9B | 6.4B | 92.8% |
| Y2 | 56.6B | 7.6B | 6.6B | 86.1% |
| Y3 | 62.5B | 8.4B | 6.7B | 79.9% |
| Y4 | 69.1B | 9.3B | 6.9B | 74.2% |
| Y5 | 76.3B | 10.3B | 7.1B | 68.8% |
| Y6 | 80.4B | 10.9B | 6.9B | 63.9% |
| Y7 | 84.6B | 11.4B | 6.8B | 59.3% |
| Y8 | 89.1B | 12B | 6.6B | 55.0% |
| Y9 | 93.9B | 12.7B | 6.5B | 51.0% |
| Y10 | 98.8B | 13.3B | 6.3B | 47.4% |
| Terminal | — | — | 123.1B | — |
Educational DCF model only — not financial advice. Terminal value and assumptions dominate results; verify filings and run your own diligence.